MedTrace Logo

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

NCT01782976 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-01-19

No results posted yet for this study

Summary

The goal of this clinical research study is to learn if cilengitide given in combination with bevacizumab can help to control glioblastoma. The safety of this drug combination will also be studied.

Cilengitide is designed to block the flow of blood to cancer cells, which may help to slow or block the growth of cancer.

Bevacizumab is designed to block the growth of new blood vessels, which may help to slow or block the growth of cancer.

Conditions

Interventions

DRUG

Cilengitide

2000 mg by vein twice weekly of each 28 day cycle.

DRUG

Bevacizumab

10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.

BEHAVIORAL

Questionnaire

Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.

Sponsors & Collaborators

  • Brain Tumor Trials Collaborative

    collaborator OTHER

  • EMD Serono

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Mark R. Gilbert, MD,BS · UT MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2017-06-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01782976 on ClinicalTrials.gov